AtriCure's improved tissue ablator:
This article was originally published in Clinica
The US FDA has given AtriCure 510(k) marketing clearance to use its Isolator Synergy bipolar ablation system on soft tissue. The device is a next generation version of the firm's FDA-cleared Isolator bipolar ablation system; neither product has yet been cleared for cardiac use or for treating atrial fibrillation. It incorporates two pulsing pairs of electrodes in the jaws of the clamp to create a uniform, full-thickness ablation lesion shaped like a column, which the West Chester, Ohio firm believes will result in more durable ablation lines in thicker and more diseased tissues. The company anticipates launching a minimally-invasive version of the device during the third quarter of 2007.